Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Report Overview
2023
Base Year
2018-2023
Historical Year
2024-2032
Forecast Year
Renal Cell Carcinoma Market Trends
| Key Trends | Description |
| Advancements in Targeted Therapies | Advancement in targeted therapies, such as tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors, that specifically target molecular pathways involved in cancer growth is shifting the market dynamics. These therapies offer improved efficacy and safety profiles over traditional treatments. |
| Rise of Immunotherapy Combinations | Combining different immunotherapies with targeted therapies has emerged as a promising approach in renal cell carcinoma treatment. These combinations show potential for improved survival rates in advanced RCC cases. |
| Increasing Prevalence of Renal Cell Carcinoma | The global incidence of RCC is rising, attributed to factors such as aging population and increased exposure to risk factors like smoking and obesity. This will fuel research and development efforts in the therapy market. |
| Precision Medicine and Biomarker Development | There is a growing emphasis on precision medicine in RCC treatment, focusing on the identification of biomarkers that can predict response to specific therapies. This approach will optimize outcomes and minimize side effects. |
Renal Cell Carcinoma Market Report Snapshots
Renal Cell Carcinoma Market Size
Renal Cell Carcinoma Market Trends
Renal Cell Carcinoma Treatment Companies
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Looking for specific insights?
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Key Questions Answered in the Report
The market is anticipated to grow at a CAGR of 4.4% during the forecast period of 2024-2032, driven by the rising prevalence of renal cell carcinoma across 8 major markets.
The market demand is driven by the advancement in targeted therapies and heightened patient awareness. Increasing investments to develop effective therapeutic alternatives is another factor driving market demand.
One of the significant market trends is the rise in fast-track designations and accelerated approvals from regulatory bodies. In September 2023, the United States FDA granted priority review designation to supplemental new drug application (sNDA) for belzutifan (Welireg) to treat advanced renal cell carcinoma.
Based on the indication type, the market is segmented into chromophobe RCC, papillary RCC, clear cell RCC, and others.
By dosage form, the market is segmented into capsules, tablets, injections, and others.
The route of administration includes oral, parenteral, and other routes.
The treatment types of the market are surgery, chemotherapy, targeted therapy, ablation, medication, and others.
Major end users of the market are hospitals, specialty clinics, homecare settings, and other healthcare facilities.
Distribution channels in the market include hospital pharmacies, retail pharmacies, online pharmacies, and other channels.
Diagnostic methods available in the market include biopsy, ultrasound, blood tests, nephrectomy, CT scans, urine tests, and others.
The major regions of the market include the United States, EU-4 (Germany, France, Italy, Spain), United Kingdom, Japan, and China.
Key players involved in the market are Bausch Health Companies Inc., LEO Pharma A/S, Merck KGaA, AbbVie Inc., Abbott, Cipla Inc., Johnson & Johnson Private Limited, AstraZeneca, Merck & Co., Inc., Mylan N.V., Eli Lilly and Company, Bayer AG, Novartis AG, GlaxoSmithKline plc, and Pfizer.
Purchase Full Report
Datasheet
- Selected Sections, One User
- Printing Not Allowed
- Email Delivery in PDF
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Single User License
One User
- All Sections, One User
- One Print Allowed
- Email Delivery in PDF
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
Five Users
- All Sections, Five Users
- Five Prints Allowed
- Email Delivery in PDF
- Free Limited Customisation
- Post Sales Analyst Support
50% Discount on Next Update
Corporate License
Unlimited Users
- All Sections, Unlimited Users
- Unlimited Prints Allowed
- Email Delivery in PDF + Excel
- Free Limited Customisation
- Post Sales Analyst Support
- 50% Discount on Next Update
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
- Our Insights Store:
-
Industry Statistics
-
Procurement Insights
-
Consumer Insights
Our Offices
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124